]
  • Home
  • News
  • News
  • NICE recommend golimumab as an option for non radiographic axial spondyloarthritis
Last updated:10th January 2018

NICE recommend golimumab as an option for non radiographic axial spondyloarthritis

NICE (National Institute for Health and Care Excellence) have announced golimumab (Simponi) is now recommended, within its marketing authorisation, as an option for treating severe non-radiographic axial spondyloarthritis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs.

Golimumab was already recommended by NICE for ankylosing spondylitis.

NICE already recommends adalimumab, etanercept and certolizumab pegol for treating non-radiographic axial spondyloarthritis. Because golimumab has similar overall health benefits and costs to adalimumab, etanercept and certolizumab pegol, NICE have recommended it for treating non-radiographic axial spondyloarthritis in the NHS.

It means that there's another option for people with non-radiographic axial spondyloarthritis.

 


Give

Join

Shop

Your privacy is important to us. We want to be sure you know how and why we use your data. View our Privacy Statement for more details. This also includes information on how we use cookies.

Accept